Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery

Yhee, Ji Young; Im, Jintaek; Nho, Richard Seonghun

doi:10.3390/jcm5090082

Cited by 98 publications

(55 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhalation therapy poses a distinct advantage in distributing these drugs evenly and locally within the lungs, reaching all CPD‐afflicted tissues in a controllable manner (Sahib, Abdulameer, Darwis, Peh, & Tan, ). Inhalation of nanotherapeutic systems is currently being extensively studied and has great potential for targeted drug delivery in the treatment of CPDs (Ratemi, Sultana Shaik, Al Faraj, & Halwani, ; Yhee, Im, & Nho, ).…”

Section: Inhalable Therapeutics For Chronic Pulmonary Diseases (Cpds)mentioning

confidence: 99%

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Anderson

Grimmett

Domalewski

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Respiratory illnesses are prevalent around the world, and inhalation‐based therapies provide an attractive, noninvasive means of directly delivering therapeutic agents to their site of action to improve treatment efficacy and limit adverse systemic side effects. Recent trends in medicine and nanoscience have prompted the development of inhalable nanomedicines to further enhance effectiveness, patient compliance, and quality of life for people suffering from lung cancer, chronic pulmonary diseases, and tuberculosis. Herein, we discuss recent advancements in the development of inhalable nanomaterial‐based drug delivery systems and analyze several representative systems to illustrate their key design principles that can translate to improved therapeutic efficacy for prevalent respiratory diseases. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease

show abstract

Section: Inhalable Therapeutics For Chronic Pulmonary Diseases (Cpds)mentioning

confidence: 99%

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Anderson

Grimmett

Domalewski

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…A) Schematic illustration of four nanoparticle platforms for antimicrobial drug delivery: (from left to right) liposome, solid lipid nanoparticle, polymeric nanoparticle, and dendrimer. Reproduced with permission . Copyright 2016, MDPI.…”

Section: Nanoparticle‐based Delivery Systems For Antibioticsmentioning

confidence: 99%

Reducing Bacterial Infections and Biofilm Formation Using Nanoparticles and Nanostructured Antibacterial Surfaces

Shi

Wang

et al. 2018

Adv Healthcare Materials

177

108

View full text Add to dashboard Cite

With the rapid spreading of resistance among common bacterial pathogens, bacterial infections, especially antibiotic-resistant bacterial infections, have drawn much attention worldwide. In light of this, nanoparticles, including metal and metal oxide nanoparticles, liposomes, polymersomes, and solid lipid nanoparticles, have been increasingly exploited as both efficient antimicrobials themselves or as delivery platforms to enhance the effectiveness of existing antibiotics. In addition to the emergence of widespread antibiotic resistance, of equal concern are implantable device-associated infections, which result from bacterial adhesion and subsequent biofilm formation at the site of implantation. The ineffectiveness of conventional antibiotics against these biofilms often leads to revision surgery, which is both debilitating to the patient and expensive. Toward this end, micro- and nanotopographies, especially those that resemble natural surfaces, and nonfouling chemistries represent a promising combination for long-term antibacterial activity. Collectively, the use of nanoparticles and nanostructured surfaces to combat bacterial growth and infections is a promising solution to the growing problem of antibiotic resistance and biofilm-related device infections.

show abstract

“…Respiratory disease, also known as pulmonary or lung disease, is a general term used to describe any conditions that affect the lungs and other parts of the respiratory system. In this review, the respiratory diseases discussed include asthma, acute lung inflammation, acute lung injury, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), lung cancer, and lung infection (Chughtai & O'riordan, ; Kim, Paudel, & Kim, ; Patil & Deshpande, ; Wang et al, ; Yhee, Im, & Nho, ).…”

Section: Introductionmentioning

confidence: 99%

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Chellappan

Yee

Xuan

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Neutrophils are essential effector cells of immune system for clearing the extracellular pathogens during inflammation and immune reactions. Neutrophils play a major role in chronic respiratory diseases. In respiratory diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, lung cancer and others, there occurs extreme infiltration and activation of neutrophils followed by a cascade of events like oxidative stress and dysregulated cellular proteins that eventually result in apoptosis and tissue damage. Dysregulation of neutrophil effector functions including delayed neutropil apoptosis, increased neutrophil extracellular traps in the pathogenesis of asthma, and chronic obstructive pulmonary disease enable neutrophils as a potential therapeutic target. Accounting to their role in pathogenesis, neutrophils present as an excellent therapeutic target for the treatment of chronic respiratory diseases. This review highlights the current status and the emerging trends in novel drug delivery systems such as nanoparticles, liposomes, microspheres, and other newer nanosystems that can target neutrophils and their molecular pathways, in the airways against infections, inflammation, and cancer. These drug delivery systems are promising in providing sustained drug delivery, reduced therapeutic dose, improved patient compliance, and reduced drug toxicity. In addition, the review also discusses emerging strategies and the future perspectives in neutrophil-based therapy. K E Y W O R D S nanoparticle, neutrophils, novel drug delivery, pulmonary, respiratory diseases

show abstract

Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery

Cited by 98 publications

References 114 publications

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Reducing Bacterial Infections and Biofilm Formation Using Nanoparticles and Nanostructured Antibacterial Surfaces

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Contact Info

Product

Resources

About